{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:43:24Z","timestamp":1769114604581,"version":"3.49.0"},"reference-count":22,"publisher":"BMJ","issue":"24","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["CS\/15\/1\/31175"],"award-info":[{"award-number":["CS\/15\/1\/31175"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pharmacosmos A\/S","award":["See manuscript for more details"],"award-info":[{"award-number":["See manuscript for more details"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2022,7,12]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>For patients with a reduced left ventricular ejection fraction (LVEF) heart failure with reduced ejection fraction (HFrEF) and iron deficiency, administration of intravenous iron improves symptoms, exercise capacity and may in the following 12 months, reduce hospitalisations for heart failure. The Effectiveness of <jats:italic>I<\/jats:italic>nt<jats:italic>r<\/jats:italic>avenous ir<jats:italic>on<\/jats:italic> treat<jats:italic>m<\/jats:italic>ent versus standard care in p<jats:italic>a<\/jats:italic>tie<jats:italic>n<\/jats:italic>ts with heart failure and iron deficiency (IRONMAN) trial evaluated whether the benefits of intravenous iron persist in the longer term and impact on morbidity and mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>IRONMAN is a prospective, randomised, open-label, blinded endpoint (PROBE) event-driven trial. Patients aged \u226518 years with HFrEF (LVEF \u226445%) and evidence of iron deficiency (ferritin &lt;100\u2009\u00b5g\/L and\/or TSAT &lt;20%) were enrolled if they had either a current or recent hospitalisation for heart failure or elevated plasma concentrations of a natriuretic peptide. Participants were randomised to receive, or not to receive, intravenous ferric derisomaltose in addition to guideline-recommended therapy for HFrEF. Every 4\u2009months, intravenous iron was administered if either ferritin was &lt;100\u2009\u00b5g\/L or, provided ferritin was \u2264400\u2009\u00b5g\/L, TSAT was &lt;25%. The primary endpoint is a composite of total hospitalisations for heart failure and cardiovascular death. Hospitalisation and deaths due to infection are safety endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Trial recruitment was completed across 70 UK hospital sites in October 2021. Participants were followed until the end of March 2022. We plan to report the results by November 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>IRONMAN will determine whether repeated doses of intravenous ferric derisomaltose are beneficial and safe for the long-term treatment of a broad range of patients with HFrEF and iron deficiency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02642562\">NCT02642562<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2022-321304","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T13:28:16Z","timestamp":1660138096000},"page":"1979-1985","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Rationale and design of a randomised trial of intravenous iron in patients with heart failure"],"prefix":"10.1136","volume":"108","clinical-trial-number":[{"clinical-trial-number":"nct02642562","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03036462","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02642562","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5288-3074","authenticated-orcid":false,"given":"Paul R","family":"Kalra","sequence":"first","affiliation":[{"name":"Department of Cardiology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK"},{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John GF","family":"Cleland","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-9496","authenticated-orcid":false,"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK"},{"name":"Golden Jubilee National Hospital, Clydebank, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-0180","authenticated-orcid":false,"given":"Fozia Z","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, The University of Manchester Faculty of Biology Medicine and Health, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-832X","authenticated-orcid":false,"given":"Paul WX","family":"Foley","sequence":"additional","affiliation":[{"name":"Great Western Hospital, Swindon, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-1572","authenticated-orcid":false,"given":"Philip A","family":"Kalra","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6887","authenticated-orcid":false,"given":"Ninian N","family":"Lang","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9650-5358","authenticated-orcid":false,"given":"Rebecca E","family":"Lane","sequence":"additional","affiliation":[{"name":"Part of Guy's and St Thomas' NHS Foundation Trust, Royal Brompton and Harefield Hospitals, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9098-8611","authenticated-orcid":false,"given":"Iain C","family":"Macdougall","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, King's College Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-0464","authenticated-orcid":false,"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4166-3746","authenticated-orcid":false,"given":"Michael T B","family":"Pope","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-8368","authenticated-orcid":false,"given":"Michele","family":"Robertson","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6282-4318","authenticated-orcid":false,"given":"Iain B","family":"Squire","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester, UK"},{"name":"NIHR Leicester Biomedical Research Centre Cardiovascular Diseases, Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-8479","authenticated-orcid":false,"given":"Elizabeth A","family":"Thomson","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-1823","authenticated-orcid":false,"given":"Ian","family":"Ford","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"2025100702383484000_108.24.1979.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.027"},{"key":"2025100702383484000_108.24.1979.2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jamacardio.2016.1161","article-title":"Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure","volume":"1","author":"Cleland","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2025100702383484000_108.24.1979.3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for iron deficiency in patients with heart failure","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025100702383484000_108.24.1979.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908355"},{"key":"2025100702383484000_108.24.1979.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu385"},{"key":"2025100702383484000_108.24.1979.6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2025100702383484000_108.24.1979.7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00392-021-01837-8","article-title":"Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials","volume":"110","author":"Graham","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2025100702383484000_108.24.1979.8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33935","article-title":"Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis","volume":"4","author":"Shah","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025100702383484000_108.24.1979.9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J Royal Statistical Soc B"},{"key":"2025100702383484000_108.24.1979.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00554.x"},{"key":"2025100702383484000_108.24.1979.11","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ejhf.1710","article-title":"Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure","volume":"21","author":"Ponikowski","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025100702383484000_108.24.1979.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.5427"},{"key":"2025100702383484000_108.24.1979.13","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab040"},{"key":"2025100702383484000_108.24.1979.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs277"},{"key":"2025100702383484000_108.24.1979.15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","article-title":"Comparison of time-to-first event and recurrent-event methods in randomized clinical trials","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"key":"2025100702383484000_108.24.1979.16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/phar.2075","article-title":"PARADIGM-HF trial: secondary analyses address unanswered questions","volume":"38","author":"Smith","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2025100702383484000_108.24.1979.17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00045"},{"key":"2025100702383484000_108.24.1979.18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019090972"},{"key":"2025100702383484000_108.24.1979.19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008100","article-title":"Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design","volume":"14","author":"Mentz","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2025100702383484000_108.24.1979.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2025100702383484000_108.24.1979.21","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2025100702383484000_108.24.1979.22","unstructured":"National Institue for Health and Care Excellence . Chronic heart failure in adults: diagnosis and management, NICE guideline (NG106). London: NICE, 2018."}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2022-321304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:38:48Z","timestamp":1759829928000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2022-321304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":22,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,11,24]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/heartjnl-2022-321304"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2022-321304","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]}}}